StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals Direct Clinical R&D by Quarter

Direct Clinical R&D — EYLEA (2 mg) [legacy through FY22] ($M) ($M)

Regeneron Pharmaceuticals Direct Clinical R&D: $16.3M in Q2 2022, down 39.0% from a year earlier. No newer figure appears in the documents we track.

Latest, Q2 2022
16.3
Period ended Jun 30, 2022
Change on a year earlier
-39.0%
26.7 in Q2 2021
History
14 quarters
Since Q1 2019
Sources
10
Documents cited below

Where the Q2 2022 figure comes from

“R&D Expenses Table (FY2022Q2): EYLEA | 16.3 | 26.7 | (10.4) | 40.7 | 54.8 | (14.1)”

Source: Form 10-Q (regn-20220630.htm, filed 2022-08-03) ↗

Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses by Clinical Program.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Direct Clinical R&D ($M), quarterly Q1 2019–Q2 2022 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-prog-eylea-leg

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?